Bentley University

Scholars @ Bentley
Natural & Applied Sciences Faculty Publications

Department of Natural and Applied Sciences

2013

Could Human Genome Sciences have become Standard Oil?
Fred D. Ledley

Follow this and additional works at: https://scholars.bentley.edu/nas_facpubs
Part of the Genetics and Genomics Commons

Blog: Could Human Genome Sciences have become
Standard Oil?
Human Genome Sciences (HGS) was not a company with
normal ambitions. At its inception, HGS aspired to dominate
not only the field of genomic science, but also emerging
markets for regenerative medicines designed to meet the
needs of ageing populations. Fred Ledley asks whether HGS
could have become the Standard Oil of our generation.
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Human Genome Sciences (HGS) was not a company with normal ambitions. From its
founding in 1992, HGS aspired to dominate the newly emergent field of genomics. The
company’s strategy was not simply to mine the human genome for novel sequence
elements that could be refined into drug targets or biological products, but rather to use
“omics” approaches to systematize and automate biopharmaceutical development.
Moreover the company’s intent was not only to develop novel therapeutic products, but to
discover regenerative medicines that would meet the needs of ageing populations. The
company’s ambitions were evident in annual reports that featured Greek gods and saints as
metaphors for the company’s quest along with headlines such as “towards victory over
disease” (1998) and “the new face of pharmaceuticals” (2000).
A recent paper from our group (McNamee, L.M., Ledley, F.D. (2013) Assessing the history
and value of Human Genome Sciences. J. Com. Biotech. 19) examined the history of HGS,
focusing on the relationship between capital investments, the company’s valuation, its
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accumulation of intellectual property, and its product pipeline. This technical analysis
highlighted the failure of markets to value HGS’ intellectual property portfolio or product
pipeline, which ultimately caused the company to be acquired by GlaxoSmithKline (GSK) for
a “fair value” that was less than the total capital investment in the company.
Given HGS’ early ambitions, however, the more interesting question may be “could HGS
have become Standard Oil? The question is not entirely facetious.
Like HGS, Standard Oil was at the forefront of the science and technological innovations of
its era. Standard Oil initially grew to prominence with its patented Frasch-Burton process
for fractional distillation, which enabled the company to produce kerosene from the highsulphur oils being discovered in Ohio. The company continued to invest in research and, in
the words of the US Supreme Court, was “…unremitting in their efforts to improve the
processes of refining.”
Standard Oil was not the only corporate enterprise to emerge from the inventions and
innovations of the 19th and early 20th centuries. Carnegie Steel, later US Steel, was the first
US company to license the revolutionary Bessemer Process for steel production, American
Tobacco was an early adopter of the automated cigarette rolling, and companies like
General Electric, Westinghouse, and AT&T were organized around innovations in electricity
and communications. So too, the modern pharmaceutical industry emerged during this era
based on advances in organic chemistry and novel technologies such as the tablet press.
While each of these companies was at the forefront of technological innovation, they were
also at the forefront of business innovation. Standard Oil famously created a vertically
integrated enterprise that funneled oil from its wells into its transportation, refining, and
marketing network. Similarly, US Steel grew to control mining, coke and ore production,
and steel production, but also built a network of railroads and steamships, while American
Tobacco controlled the processing, production, and marketing of tobacco products. The
business innovations of the era not only improved efficiencies through vertical integration
and scale, but also mass production as well as fundamental changes in banking practices,
management, marketing,
labor relations, and business
law; not to mention the
monopolistic practices that
would ultimately cause these
companies to be
dismembered. In ordering
the break-up of Standard Oil
in 1911, the Supreme Court
noted that the company was
“…guided by economic genius
of the highest order,
sustained by courage, by a

keen insight into commercial situations, resulting in the acquisition of great wealth, but at
the same time serving to stimulate and increase production, to widely extend the
distribution of the products of petroleum at a cost largely below that which would have
otherwise prevailed…”
Perhaps HGS could never have become Standard Oil. Perhaps the innovations arising from
the “omics” era are not as great as those that empowered the great corporations of the late
19th and early 20th centuries. Perhaps the potential markets for products of these
innovations are not as large. While these reservations may be fairly debated, what is clear is
that there have been no innovations in the business models for “omics” comparable to
those that accompanied the technological innovations of the earlier age.
HGS, and other companies comprising the genomic sector, adopted business models that
were familiar to the venture capitalists and the biopharmaceutical industry, and most were
eventually acquired and seamlessly integrated into established pharmaceutical companies.
While some individuals acquired significant wealth from genomics (HGS’ CEO was briefly
biotech’s first billionaire in 2000), it is hard to imagine critics of the industry describing its
leaders as “economic genius of the highest order.”
It may, in fact, be silly to consider similarities between HGS and Standard Oil; there are
simply too many differences. But that is exactly the point. Genomic technologies, and the
market opportunities for biopharmaceuticals to manage the health and wellness of ageing
populations, are unprecedented. Nevertheless, while HGS avidly embraced innovation in
science and technology, it failed to explore comparable innovations in business.
Business models have been described as “a focusing device that mediates between
technology development and economic value creation,” and an extensive body of research
suggests that successful innovation requires an effective synergy between a company’s
technologies and business model. Could HGS have become Standard Oil with critical
innovations in business to complement their novel technologies? We will never know.

